Therapeutics News and Research

RSS

Minnesota researchers develop animal research model for FSHD

Researchers at the University of Minnesota have developed an animal research model for facioscapulohumeral muscular dystrophy (FSHD) to be used for muscle regeneration research as well as studies of the effectiveness of potential therapies for FSHD.

29 Aug 2014

HICCC receives $18 million grant from the National Cancer Institute

Outstanding basic research, a growing focus on translating discoveries into treatments, and a dedication to patient care have earned the Herbert Irving Comprehensive Cancer Center (HICCC) of Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 million, five-year Cancer Center Support Grant from the National Cancer Institute (NCI).

28 Aug 2014

Armetheon raises $7 million in first round of financing

Armetheon, Inc., a biopharmaceutical company focused on developing novel mid- to late-stage cardiovascular drug candidates, today announced that it has raised $7.0 million in its first round of financing.

28 Aug 2014

Versatile nanoparticles offer wide variety of diagnostic and therapeutic applications

Kit Lam and colleagues from UC Davis and other institutions have created dynamic nanoparticles (NPs) that could provide an arsenal of applications to diagnose and treat cancer.

27 Aug 2014

Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans.

26 Aug 2014

Authors emphasize benefits of calcium and vitamin D supplements on bone health

Calcium and vitamin D are essential to keeping bones strong, dense and healthy as we age, as well as preventing bone loss, osteporosis, and skeletal fractures.

26 Aug 2014

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly is a chronic, life-threatening disease triggered by a benign tumour of the pituitary gland causing excessive growth hormone release. Oversupply of growth hormone stimulates liver, fat and kidney cells to produce excess levels of Insulin-Like Growth Factor I (IGFI), which causes abnormal growth of the bones of the hands, face and feet and bodily organs.

26 Aug 2014

Researchers find more selective therapies for cancer

Thanks to important discoveries in basic and clinical research and technological advances, the fight against cancer has mobilized into a complex offensive spanning multiple fronts.

25 Aug 2014

Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology platform.

25 Aug 2014

Aldea Pharmaceuticals announces closure of $24M Series B equity financing

Aldea Pharmaceuticals, a company pioneering novel therapeutics to treat aldehyde metabolism disorders, today announced that it has closed a $24 million Series B equity financing.

25 Aug 2014

Physician develops new device to treat stroke more effectively

A new device developed by a physician at the University of Arkansas for Medical Sciences and a researcher at the University of Arkansas at Little Rock could soon be available to treat stroke more effectively.

22 Aug 2014

Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

The Perelman School of Medicine at the University of Pennsylvania has launched the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to build on its previous success developing novel therapies for the personalized diagnosis and treatment of retinal and ocular disorders.

22 Aug 2014

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Nektar Therapeutics reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.

From Baxter International Inc. 22 Aug 2014

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.

20 Aug 2014

Scientists identify biomarker strongly associated with aggressive breast cancer

Two Northwestern University scientists have identified a biomarker strongly associated with basal-like breast cancer, a highly aggressive carcinoma that is resistant to many types of chemotherapy. The biomarker, a protein called STAT3, provides a smart target for new therapeutics designed to treat this often deadly cancer.

20 Aug 2014

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo Therapeutics Inc., today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs.

19 Aug 2014

Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Globavir Biosciences, Inc., a biotechnology company developing therapeutics to treat infectious diseases, has announced intentions to develop its lead drug candidate, GBV006, for the treatment of the current Ebola Virus outbreak in West Africa. Globavir will seek approval for the use of GBV006, a combination of Food and Drug Administration approved drugs, through an established compassionate use regulatory pathway.

19 Aug 2014

Researchers develop new lung-on-chip model for laboratory studies of respiratory challenges

Researchers at RTI International, in collaboration with the University of North Carolina at Chapel Hill, have developed a new lung-on-chip microdevice for laboratory studies of respiratory challenges and therapeutics. The microdevice includes multiple vertically stacked cellular layers that mimic the structure of the airway tissue.

15 Aug 2014

Finding suggests that aspirin could play role in reducing breast cancer mortality

Researchers have discovered that women who had been prescribed aspirin regularly before being diagnosed with breast cancer are less likely to have cancer that spread to the lymph-nodes than women who were not on prescription aspirin. These women are also less likely to die from their breast cancer.

15 Aug 2014

Modified C. novyi-NT bacterium produces precisely targeted anti-tumor response

A modified version of the Clostridium novyi (C. novyi-NT) bacterium can produce a strong and precisely targeted anti-tumor response in rats, dogs and now humans, according to a new report from Johns Hopkins Kimmel Cancer Center researchers.

14 Aug 2014

Therapeutics News and Research

Minnesota researchers develop animal research model for FSHD

HICCC receives $18 million grant from the National Cancer Institute

Armetheon raises $7 million in first round of financing

Versatile nanoparticles offer wide variety of diagnostic and therapeutic applications

Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Authors emphasize benefits of calcium and vitamin D supplements on bone health

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Researchers find more selective therapies for cancer

Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Aldea Pharmaceuticals announces closure of $24M Series B equity financing

Physician develops new device to treat stroke more effectively

Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Scientists identify biomarker strongly associated with aggressive breast cancer

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Researchers develop new lung-on-chip model for laboratory studies of respiratory challenges

Finding suggests that aspirin could play role in reducing breast cancer mortality

Modified C. novyi-NT bacterium produces precisely targeted anti-tumor response

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News